Social support and memory in postmenopausal women: a careful null
A secondary analysis of the ELITE hormone-therapy trial found hints that social ties tracked with cognition, but none survived correction for multiple testing.
The FDA pulled menopause hormone therapy's boxed warning. Prescribing was already rising.
Six products got revised labels in February 2026, removing cardiovascular, breast cancer, and dementia language. The scientific societies that welcomed the change also listed the distinctions the new label does not make.
Women with a pre-eclampsia history had lower breast cancer risk, Finnish data show
A Finnish registry of over 123,000 women found pre-eclampsia linked to an 11% lower breast cancer risk decades later. Hormone therapy raised risk by a similar amount in both groups.
Estrogen beat progestin alone in perimenopause, with three times more side effects
A 150-woman real-world comparison found combination therapy cut symptom scores further and produced more clinical responders. Endometrial thickness rose slightly but stayed normal.
After hysterectomy, endometriosis patients used hormone therapy far more than others
A Finnish national registry of over 11,000 women found up to 94% of endometriosis patients used menopausal hormone therapy after surgery, against 82% of a comparison group. The mix of hormones used is changing too.
A 34-study meta-analysis splits hormone therapy's breast cancer signal by regimen
Pooling decades of research, the combined estrogen-progestin regimen showed a 44% higher breast cancer risk. Estrogen-only therapy showed none in observational studies — and trials suggested it lowered risk.
In premenopausal survivors, tamoxifen was linked to fivefold endometrial hyperplasia
A Taiwanese cohort of 26,000 women aged 20 to 50 puts numbers on a known tamoxifen risk in a population — younger, premenopausal — where data has been thinner.
Denmark followed 877,000 women for 14 years. Hormone therapy did not raise mortality.
A nationwide register study found a hazard ratio of 0.96 for all-cause death among users of menopausal hormone therapy. The raw death rate in users was higher — which is the part worth understanding.
A 25-member panel says hormone therapy after breast cancer should be a shared decision
The consensus statement does not claim the treatment is safe after breast cancer. It says some women may reasonably accept an increased relapse risk in exchange for symptom relief.
A million women's worth of data on hormone therapy and dementia returns a flat line
Pooling ten studies, researchers found menopause hormone therapy neither raised nor lowered dementia risk. The certainty of that evidence ranged from moderate to very low.
Asked which menopause symptom mattered most, 7,285 women said brain fog
A UK-wide survey found cognitive and psychological symptoms outranked the ones menopause care is organised around, with higher ratings among Asian and Black respondents.
Endometriosis does not always stop at menopause. A European guide says so
An EMAS clinical guide sets out how to manage endometriosis after menopause, advising against oestrogen-only hormone therapy even in women who have had a hysterectomy.